NASDAQ: PCVX · Life Sciences · 10 alerts · CIK 1649094
Share price
$61.61Close, Nov 16
Market cap
$9.75B
Shares outstanding
158.3MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vaxcyte, Inc. filings on SEC EDGAR ↗
Vaxcyte Chief Technical Ops Officer Harpreet S. Dhaliwal Sells $1.15M of Stock
Harpreet S. Dhaliwal, Chief Technical Ops Officer, sold 17,000 shares of Vaxcyte, Inc. at $67.33 to $68.82 a share (average $67.83) in 3 transactions, worth $1.15M in total on Nov 11, 2026. Shares held after the trade: 68,085 (-0.8%).
Vaxcyte SVP, Finance & CAO Elvia Cowan Sells $183K of Stock
Elvia Cowan, SVP, Finance & CAO, sold 3,000 shares of Vaxcyte, Inc. at $60.77 to $61.55 a share (average $60.92) in 2 transactions, worth $183K in total on Nov 2, 2026. Shares held after the trade: 27,860 (-2.1%).
Vaxcyte EVP, Chief Scientific Ofc, COO Jim Wassil Sells $137K of Stock
Jim Wassil, EVP, Chief Scientific Ofc, COO, sold 2,250 shares of Vaxcyte, Inc. at $60.78 to $61.57 a share (average $60.90) in 2 transactions, worth $137K in total on Nov 2, 2026. Shares held after the trade: 145,435 (-0.2%).
Vaxcyte, Inc. is a large accelerated filer in the clinical or preclinical stages of vaccine development, reporting 158,299,981 shares of common stock outstanding as of November 2, 2026. The company continues to incur significant net losses and requires substantial additional funding to advance its pneumococcal conjugate vaccine candidates and cell-free protein synthesis platform.
Vaxcyte reported third quarter 2026 financial results and provided a business update, highlighting positive topline Phase 3 data for its VAX-31 adult pneumococcal vaccine candidate. The company strengthened its balance sheet with $1.1 billion in net proceeds from October equity and debt offerings, resulting in a pro forma cash position of approximately $3.4 billion. Vaxcyte remains on track for a planned BLA submission for VAX-31 in the first half of 2028.
Term
Q3 2026
“The positive topline results from OPUS-1 represent a significant milestone for Vaxcyte and our broad-spectrum pneumococcal conjugate vaccine (PCV) franchise. VAX-31 met all prespecified primary endpoints in this pivotal Phase 3 trial, which inaugurated a more stringent noninferiority standard, and we believe the results further support its potential best-in-class profile.”
Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte
“Following our positive OPUS-1 results, we completed concurrent equity and convertible senior notes offerings, raising approximately $1.1 billion in net proceeds, to further strengthen our balance sheet and extend our cash runway. With approximately $3.4 billion in pro forma cash, cash equivalents and investments as of September 30, 2026, we are well positioned to support the potential U.S. commercial launch of VAX-31 for adults and advance our other key initiatives.”
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte